Longeveron Inc. (LGVN)

NCM – Real Time Price. Currency in USD

0.75

-0.09 (-10.48%)

At close: May 12, 2026, 4:00 PM EDT

0.76

+0.01 (1.32%)

Pre-market: May 13, 2026, 8:54 AM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Longeveron Inc. (LGVN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Longeveron Inc. (LGVN)

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Longeveron Braces For Q4 Results Following Recent Funding Boost

Videos

No Data

Press releases

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Search stocks

Longeveron Inc. (LGVN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Longeveron Inc. (LGVN)

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Longeveron Braces For Q4 Results Following Recent Funding Boost

Videos

No Data

Press releases

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update